https://peptide.zone/story/glp-1-allodynia-burning-skin-reportsPeptide Zoneen2026-11-06T04:27:00.000ZGLP 1 allodynia reports link weight loss drugs to burning skin pain https://peptide.zone/story/hhs-peptide-compounding-policy-evidence-questionsPeptide Zoneen2026-11-06T03:37:00.000ZHHS peptide compounding policy faces evidence questions before comment deadline https://peptide.zone/story/glp-1-side-effects-hair-loss-visionPeptide Zoneen2026-11-06T03:03:00.000ZGLP 1 side effects range from common hair loss to rare vision loss https://peptide.zone/story/rogaine-sales-30-percent-glp-1Peptide Zoneen2026-11-06T02:13:00.000ZRogaine sales up 30 percent this year as CEO links rise to GLP 1 drugs https://peptide.zone/story/camurus-monthly-semaglutide-depot-phase-2bPeptide Zoneen2026-11-05T04:34:00.000ZCamurus starts Phase 2b trial of monthly semaglutide depot CAM2056 https://peptide.zone/story/pegcetacoplan-c3g-adolescents-proteinuria-76-weeksPeptide Zoneen2026-11-05T04:11:00.000ZPegcetacoplan C3G data show proteinuria cut holds at 76 weeks in adolescents https://peptide.zone/story/wegovy-pill-market-share-novo-outlookPeptide Zoneen2026-11-05T03:37:00.000ZWegovy pill market share holds near 80 percent as Novo raises outlook https://peptide.zone/story/glp-1-dose-hacking-christmas-gpsPeptide Zoneen2026-11-05T03:05:00.000ZGLP 1 dose hacking for Christmas draws caution from UK GPs